Streuli Isabelle, Fraisse Timothée, Ibecheole Victoria, Moix Isabelle, Morris Michael A, de Ziegler Dominique
Division of Reproductive Endocrinology and Infertility, University Hospitals of Geneva, Geneva, Switzerland.
Fertil Steril. 2009 Aug;92(2):464-70. doi: 10.1016/j.fertnstert.2008.07.007. Epub 2008 Oct 29.
To compare the prevalence of intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency (oPOI) and in controls.
Observational study.
Division of Infertility and Service of Genetic Medicine, Geneva University Hospitals.
PATIENT(S): The study group consisted of 27 infertile women with oPOI referred by infertility specialists for FMR1 testing in 2005-6 because of unexplained poor response to controlled ovarian hyperstimulation or altered hormonal profiles. The control group consisted of 32 women undergoing genetic testing for conditions unrelated to mental retardation or ovarian function. The DNA samples were anonymized.
INTERVENTION(S): In the study group, data were collected concerning reproductive/family history, hormonal markers, possible fertility treatment outcomes, and results of karyotype and FMR1 testing. In the control group, FMR1 gene testing was done. The only clinical data available in controls were sex and indication for genetic testing.
MAIN OUTCOME MEASURE(S): Distribution of FMR1 alleles.
RESULT(S): Six (22%) of 27 women with oPOI had FMR1 alleles of >40 repeats (intermediate to premutation range), compared with one (3%) of 32 controls.
CONCLUSION(S): These results suggest that women with oPOI might be at risk of carrying alleles in the intermediate and premutation range.
比较隐匿性原发性卵巢功能不全(oPOI)女性与对照组中FMR1基因中间型和前突变等位基因的流行率。
观察性研究。
日内瓦大学医院不孕不育科和遗传医学科。
研究组由27名不孕且患有oPOI的女性组成,她们于2005 - 2006年因对控制性卵巢过度刺激反应不佳或激素水平改变而被不孕不育专家转诊进行FMR1检测。对照组由32名因与智力发育迟缓或卵巢功能无关的疾病接受基因检测的女性组成。DNA样本进行了匿名处理。
在研究组中,收集了有关生殖/家族史、激素标志物、可能的生育治疗结果以及核型和FMR1检测结果的数据。在对照组中,进行了FMR1基因检测。对照组仅有的临床数据是性别和基因检测指征。
FMR1等位基因的分布。
27名患有oPOI的女性中有6名(22%)FMR1等位基因重复次数>40次(处于中间型至前突变范围),而32名对照组女性中有1名(3%)。
这些结果表明,患有oPOI的女性可能携带处于中间型和前突变范围等位基因的风险。